For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Group newsletter: CCTG Connection

Archived Bulletins

May 20, 2020

Published: May 20, 2020
Category: Trials
Closed to Accrual: CO28

CO28: NEOadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer: The NEO Trial has been closed to accrual after successfully reaching the accrual goal.

The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum.

Read More

Published: May 20, 2020
Category: Group updates
Dr. Michael Brundage

After 22 years in his position as QOL committee co-chair, Dr. Michael Brundage is stepping down, to be succeeded by Dr. Winson Cheung.

Read More

May 07, 2020

Published: May 07, 2020
Category: Trials
Trial Closure: IND216

The IND216 trial: Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia, has been permanently closed.

About the trial: Buparlisib has been shown to shrink tumours in animals. It has been studied in some people and seems promising but it is not clear if it can offer better results than standard treatment. The standard or usual treatment for this disease is chemotherapy, targeted therapy or radiation, either alone or in combination.

Read More

CCTG Genitourinary Disease Site Committee welcomes new chair and modality sub-chairs

The CCTG Genitourinary Disease Site Committee is very honoured to welcome the new chair and modality sub-chairs.

Read More

Published: May 07, 2020
Category: Publications

Primary publication for IND226 and MA33 QoL journal article

Read More

April 22, 2020

Published: April 22, 2020
Category: Trials

CCTG Planned Trials

ALC5 - Novel Therapeutics vs Azacitidine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial) More >>

Read More

Published: April 22, 2020
Category: Trials

CRC9 (NCT04068103), Phase II/III study of Circulating tumor DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA), has been centrally activated.

Read More

Published: April 22, 2020
Category: Group updates
COVID-19 Update: CCTG guidance documents and updated FAQ

CCTG has developed guidance documents to facilitate continuing patients on trials or how to modify (and document) protocol requirements for individual patient management as needed.

Please note that an updated Frequently Asked Questions (FAQs) document has been posted to the CCTG COVID-19 members webpage. Also new are posted links to the previously communicated important memos dated 2020MAR17, 2020MAR27 and 2020APR06.

Read More